Physician profile
Stefanie E Rollins
NPI 1467780874
$13,234.07
in general payments reported to CMS, 2019-2025
27 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,686 · 2022: $2,393 · 2023: $2,957 · 2024: $3,275 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,455 · Consulting Fee: $1,634 · Education: $66.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,455.14 |
| Consulting Fee | $1,634.00 |
| Education | $66.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,110.52 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $2,837.77 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,025.38 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Amgen INC. | $1,016.22 | 2021-2025 | Tezspire |
| Genzyme Corporation | $890.51 | 2022-2025 | |
| Optinose US, INC. | $643.60 | 2021-2025 | |
| Genentech, INC. | $535.48 | 2023-2025 | Xolair |
| Genentech USA, INC. | $492.33 | 2021-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $287.93 | 2021-2025 | Takhzyro, Eohilia |
| Pharming Healthcare, INC. | $197.82 | 2023-2024 | Ruconest |
| Csl Behring | $188.65 | 2021-2025 | Hizentra, Haegarda |
| Kaleo, INC. | $159.98 | 2021-2023 | Auvi-Q |
| Regeneron Pharmaceuticals, INC. | $142.05 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $123.71 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $112.90 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.02 | 2022 | |
| Blueprint Medicines Corporation | $89.57 | 2023-2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $58.66 | 2022-2023 | |
| Abbvie INC. | $47.26 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $45.87 | 2025 | Neffy |
| Alk-Abello, INC | $26.44 | 2022 | |
| Hologic Sales and Service, LLC | $22.14 | 2024 | Aptima, Thinprep 2000 Processor |
| Galderma Laboratories, L.P. | $21.83 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $20.92 | 2023 | Ryaltris |
| Biocryst US Sales Co., LLC | $16.48 | 2023 | Orladeyo |
| Nestle Healthcare Nutrition INC. | $16.36 | 2023 | |
| Lilly USA, LLC | $13.67 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Rollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.